L'Oreal (OREP.PA) and Nestle (NESN.VX) venture Galderma upped its offer for Q-Med (QMED.ST) to $1.16 billion on Thursday and won 78 percent acceptances as it boosts its beauty treatments in a consolidating market. Analysts said a big plus for Galderma was Q-Med's Restylane, a global leading range of products for smoothing out wrinkles and filling out the face. The medical beauty market is worth about 3.5 billion euros ($4.79 billion) a year and consolidation has been picking up. [ID:nLDE703170]
Source
